HilleVax (HLVX) Q2 2025 earnings summary

Executive summary

• Entered into a definitive merger agreement with XOMA Royalty, with shareholders to receive $1.95 per share in cash plus a contingent value right; closing anticipated in September 2025.

• Tender offer expected to commence by August 18, 2025.

• Terminated the Takeda License for HIL-214, effective six months after August 1, 2025.

• Workforce reduced by 80% during 2024, with only 12 full-time employees as of August 4, 2025.

• Report covers the quarter ended June 30, 2025, focusing on vaccine development and strategic alternatives after discontinuing HIL-214 in infants.

Financial highlights

• Net loss was $5.3 million for Q2 2025, compared to $40.7 million for Q2 2024.

• Net loss for the six months ended June 30, 2025 was $11.3 million, down from $87.5 million for the same period in 2024.

• Cash, cash equivalents, and marketable securities totaled $159.5 million as of June 30, 2025, down from $171.4 million at year-end 2024.

• Research and development expenses fell to $1.3 million in Q2 2025 from $26.6 million in Q2 2024; for the six months, R&D dropped to $3.3 million from $52.6 million year-over-year.

• General and administrative expenses fell to $11.3 million from $16.6 million year-over-year for the six-month period.

Outlook and guidance

• Existing cash and equivalents expected to fund operations for at least the next 12 months.

• No revenue expected until successful development and approval of vaccine candidates, which is not anticipated in the near term.

• Pending merger with XOMA may impact future operations and capital allocation.